DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* DBV TECHNOLOGIES *


 

2002 - IDF
Boulogne Billancourt
(near Paris)
www.dbv-technologies.com

 

Discovery, Diagnostics, Immunotherapy
Key words: Allergies, Viaskin, Epicutaneous Immunotherapy, Diallertest
Mission: to develop an innovative non invasive delivery technology, Viaskin, worldwide patented, suitable for severe allergic patients to food allergy both in diagnosis and specific epicutaneous immunotherapy (EPIT)
Clients: Pharmaceutical industry, Food industry, Cosmetics
nathalie.donne@dbv-technologies.com

Age: 14 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up (speciality pharma company) |
Managing Dir.-CEO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics]
Sc.Dir.-CSO: Benhamou (Pierre-Henri) (also, CEO) & Dupont (Bertrand) [Ensam]
Pharm.Dir.: Martin (Laurent) [Pharm.D., MBA IAE Paris, ex-Orphan Europe, Galderma, Fournier, Guerbet]
Clin.Dir: Agbotounou (Wence) [Ph.D. pharmacology, MBA ESCP, ex-Quintiles, PRA International]
Fin.Dir.-CFO: Schilansky (David) [Dauphine University, Imperial College London, ex-Ipsen, UBS Warburg, Thomson]
Dvpt. Dir: Ruban (Charles) [ex-Stallergènes, Europgroup Centrale (Lyon), Ms.Sc, Biomedical Engineering (Harvard-M.I.T), MBA (INSEAD)
BusDev:
Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, ALK-Abello (Pharma company), InnoBio, Lundbeckfond Ventures, Shire, Alto Invest, Fonds Stratégique d’Investissement (FSI), Public

Turnover (M€) : 0.16 (2009), 0.11 (2008), 0.25 (2006)
Total funding (M€) : 59.8
Last funding (M€) : 40.5
Focus : Allergy
Position : Trade
Company confirm : 28-Apr-2011

 

History
DATEMILESTONETYPETIME
2012 .10 Partnering research agreement with CIML (Centre d'Immunologie de Marseille-Luminy) on allergy mechanisms R&D [10 years]
2012 .08 Clinical trial (phase Iib, Vipes) for Viaskin Peanut in USA CLIN [10 years]
2012 .03 Listing on Euronext : 40.5 M€ (IPO) PBO [10 years]
2012 .02 Registration : FDA accepts Fast Track Designation status for Viaskin Peanut MKTG [9 years]
2011 .01 4th round-financing : 19.4 M€, including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and Alto Invest, as well as existing investors Sofinnova Partners and ALK Abello RFIND [8 years]
2010 .09 Patent : granted on Viaskin Allergen Delivery System, in USA LEGAL [8 years]
2010 .03 Nomination : Pierre-Henri Benhamou, new CEO (still CSO, research director), replacing Jean-François Biry ORGN [8 years]
2009 .09 Clinical trial (phase IIa) for Viaskin Peanut (selected by NIH and US consortium) CLIN [7 years]
2009 .09 Licensing-out of milk allergy test to Laboratoires Bioprojet for France LICOUT [7 years]
2009 .01 3rd round-financing : 6 M€, by Sofinnova Partners, ALK-Abello (Pharma company) RFINC [6 years]
2007 .11 Licensing-out of milk allergy test to Numico (today Danone) LICOUT [5 years]
2006 .01 2nd round-financing : 12.3 M€, by Sofinnova Partners and Apax Partners RFINB [3 years]
2003 .00 1st round-financing : 1.0 M€, by Cap Décisif and Créagro RFINA [0 year]
2002 .11 Company founded by Pierre-Henri Benhamou and Bertrand Dupont, with funding from ANVAR, based on new technology led by Prof. Christophe Dupont (AP-HP, Cochin Hospital) ORGF [0 year]

Actualisation / Updating: 30-Oct-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende